Description
Sf-900™ II SFM is a serum-free, protein-free insect cell culture medium optimized for the growth and maintenance of Spodoptera frugiperda (Sf9 and Sf21) cells and for large-scale production of recombinant proteins expressed using the baculovirus expression vector system (BEVS). This medium is suitable for suspension and monolayer culture methods and supports growth of other lepidopteran cell lines. Sf-900™ II SFM features:
• Superior long-term, high-density growth
• Optimized for recombinant protein production
• Serum-free, protein-free, ready-to-use formulation
• Scalable in bioreactors
Superior long-term, high-density growth
Spodoptera frugiperda (Sf9) cells grown in Sf-900™ II SFM achieve maximum cell densities of 9 to 12 x 106 cells/mL, a significant improvement over competitors' formulations and Grace’s medium (see Product Manual). Increases in maximum cell densities of 20-100% are also observed with the Lymantria dispar (Gypsy moth) and Trichoplusia ni (Tn-368; Cabbage Looper) cell lines. Sf-900™ II SFM is capable of supporting the cultures to >20 passages.
Optimized for recombinant protein production
Traditionally, Grace's medium supplemented with 10% FBS has been used for recombinant protein expression. Sf-900™ II SFM is an improved serum-free, protein-free medium designed for growth of Sf9 and other lepidopteran cell lines and production of insect virus and rDNA proteins.
Serum-free, protein-free, ready-to-use formulation
Sf-900™ II SFM is a serum-free, protein-free medium that allows for much easier purification of your protein of interest. Sf-900™ II SFM is ready to use; it does not require addition of serum, glutamine, or surfactants. Cells adapted to other commercially available serum-free media can be subcultured directly into Sf-900™ II SFM, usually without any further adaptation. Cells usually require some adaptation from serum-containing formulations.
Scalable in bioreactors
The utility of Sf-900™ II SFM in larger-scale cell culture systems was demonstrated with a 5 L Celligen™ bioreactor. Successful infections with rAcNPV were carried out producing rβ-Gal and rEPO (see Product Manual).
Product use
Customers using Gibco® Sf-900 II SFM in a manufacturing process, who have a submission with the FDA, may request a letter of authorization from us to reference our Type II Drug Master File (DMF).
cGMP manufacturing and quality system
For supply chain continuity, we manufacture Sf-900 II SFM at two separate facilities located in Grand Island, NY and Scotland, UK. Both sites are compliant with cGMP manufacturing requirements, are certified to ISO 13485, and are registered with the FDA as medical device manufacturers